Pfizer agrees to pay $345 million to resolve EpiPen pricing lawsuit By Reuters

© Reuters. FILE PHOTO: A vial and syringe are seen in front of a displayed Pfizer logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo (Reuters) – Pfizer Inc (NYSE:) has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive and unfair practices



© Reuters. FILE PHOTO: A vial and syringe are seen in front of a displayed Pfizer logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) – Pfizer Inc (NYSE:) has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan (NASDAQ:).

The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas. The deal, which requires a judge’s approval, would not resolve claims against Mylan, which is scheduled to face trial in January.

Paul Geller, a lawyer for the plaintiffs, said they were “pleased that Pfizer resolved its part of this class action lawsuit over the pricing of EpiPens.”

Pfizer, which did not admit wrongdoing, did not immediately respond to a request for comment.

The EpiPen is a handheld device that treats life-threatening allergic reactions by automatically injecting a dose of epinephrine.

The litigation followed a public outcry in 2016 after Mylan, which owns the rights to market and distribute the devices, raised the price of a pair of EpiPens to $600, from $100 in 2008, putting it in the center of an ongoing U.S. debate over the high cost of medicines.

The lawsuit accused Mylan and Pfizer, which manufactured the EpiPen for Mylan, of engaging in anticompetitive conduct that allowed them maintain a monopoly over the market for the devices and their profitable revenues.

The settlement came after U.S. District Judge Daniel Crabtree last month dismissed much of but not all of the claims against Mylan.

The remaining antitrust claims concern a patent settlement the plaintiffs say delayed the launch of a generic epinephrine auto-injector. Mylan has said it “firmly believes that Mylan’s conduct was lawful and pro-competitive.”

Mylan in 2017 agreed to pay $465 million to resolve U.S. Justice Department claims it overcharged the government for the EpiPen.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link

The Fund Times
ADMINISTRATOR
PROFILE

Posts Carousel

Leave a Comment

Your email address will not be published. Required fields are marked with *

Latest Posts

Top Authors

Most Commented

Featured Videos